Outcame of Cases With Hemolytic Uremic Syndrome Attending Assiut University Child Hospital

Outcame of Cases With Hemolytic Uremic Syndrome Attending Assiut University Child Hospital

Sponsors

Lead sponsor: Assiut University

Source Assiut University
Brief Summary

Diarrhea-associated hemolytic uremic syndrome (D+HUS) is defined as a prodrome of enteritis followed by thrombocytopenia (< 150,000/mm3), microangiopathic hemolytic anemia, and signs of variable degrees of renal damage (increase in serum Cr, proteinuria, and/or hematuria) . Our aim is to detect the most reliable early predictors of poor prognosis to identify children at major risk of bad outcome who could eventually benefit from early specific treatments.

Detailed Description

The disease is caused predominantly by Shiga toxin-producing enterohemorrhagic Escherichia coli (STEC) and is one of the most common etiologies of acute kidney injury (AKI) and an important cause of acquired chronic kidney disease in children [2]. The incidence of HUC tends to parallel the seasonal fluctuation of E.coli o175 : H7 infection which peaks between June & September. Nowadays, the incidence increases and is typically observe in infants and children, especially those aged 6 months to 4 years. A complicated disease course is defined as the development of one or more of the following manifestations: neurological dysfunction, severe bowel injury, pancreatitis, hemodynamic instability (symptomatic hypotension, multi-organ failure), cardiac (congestive heart failure, myocarditis, pericarditis, arrhythmia) or pulmonary involvement (pulmonary edema, acute respiratory distress syndrome), hematologic complications (hemorrhage), and death [1].

Many laboratory and clinical markers upon admission have been associated to severe forms of the disease, including high initial leukocyte and hematocrit levels, major extrarenal complications, dehydration and recently, the blood urea nitrogen (BUN) to serum creatinine (Cr) ratio [1], [4-6]. Treatment of D+HUS remains supportive; thus, early identification of high-risk patients can optimize their management [1-3].

Overall Status Not yet recruiting
Start Date October 1, 2018
Completion Date December 1, 2019
Primary Completion Date October 1, 2019
Study Type Observational
Primary Outcome
Measure Time Frame
Complete remission 1 year
Death 1 year
Residual renal affection 1 year
Enrollment 50
Condition
Eligibility

Sampling method: Non-Probability Sample

Criteria:

Inclusion Criteria:

- all patients less than 18 years diagnosed with Hemolytic Uremic Syndrome

Gender: All

Minimum age: N/A

Maximum age: 18 Years

Healthy volunteers: No

Overall Contact

Last name: Fahim Mohamed Fahim, Professor

Phone: 01002500073

Phone ext: 002

Email: [email protected]

Verification Date

September 2018

Responsible Party

Responsible party type: Principal Investigator

Investigator affiliation: Assiut University

Investigator full name: walaa gamal abd elrazik

Investigator title: Principal investigator

Has Expanded Access No
Condition Browse
Study Design Info

Observational model: Case-Only

Time perspective: Prospective

Source: ClinicalTrials.gov